Details for Patent: 9,089,587

Which drugs does patent 9,089,587 protect, and when does it expire?

Patent 9,089,587 protects SOOLANTRA and is included in one NDA.

This patent has forty-five patent family members in sixteen countries.

Summary for Patent: 9,089,587

Patent landscape, scope, and claims:

Title:	Treatment of papulopustular rosacea with ivermectin
Abstract:	Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
Inventor(s):	Jacovella; Jean (Sophia Antipolis, FR), Chappuis; Jean-Paul (Valbonne, FR), Sordello Wagner; Nathalie (Pegomas, FR)
Assignee:	Galderma S.A. (Chem, CH)
Application Number:	14/257,567
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,089,587
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 9,089,587

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes	9,089,587					TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

International Family Members for US Patent 9,089,587

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014287408
Australia	2014287422
Brazil	112016000335
Brazil	112016000350
Canada	2916668
Canada	2916704